NEW YORK, September 2, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Investors' Reports announced new research reports highlighting Endo Health Solutions Inc. (NASDAQ: ENDP), Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), Accuray Incorporated (NASDAQ: ARAY), and BioScrip Inc. (NASDAQ: BIOS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endo Health Solutions Inc. Research Report
On August 28, 2013, Endo Health Solutions Inc. (Endo) announced that its subsidiary, Qualitest, has reached a definitive agreement to acquire Boca Pharmacal, a privately held specialty generics company, for $225 million in cash. According to Endo, the acquisition is expected to generate EBITDA of approximately $50 million in full-year 2013 on a standalone basis. Rajiv de Silva, President and CEO of Endo, said, "The acquisition is aligned with our current generics footprint and will meaningfully accelerate the growth of Qualitest in 2014. I believe that the revenue and earnings contribution of this transaction, combined with the unique commercial portfolio and strong pipeline of ANDAs, make this an ideal fit." Endo expects the deal to close before the end of 2013, subject to standard regulatory requirements. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/ENDP]
Astex Pharmaceuticals, Inc. Research Report
On August 28, 2013, Astex Pharmaceuticals, Inc. (Astex) reported topline results from the ongoing Phase 2 trial of SGI-110 in patients with AML and MDS. The Company stated that as of the end of the June 2013 data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naïve elderly AML not suitable for induction chemotherapy cohort). According to Astex, the primary endpoint was overall remission rate (Complete Remission or CR Complete Remission with Incomplete hematologic recovery or CRi/CRp), and there were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naïve elderly AML for an overall complete remission rate of (CR, CRi/CRP0 of 17/67) or 25%. The Full Research Report on Astex Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/ASTX]
Auxilium Pharmaceuticals, Inc. Research Report
On August 28, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it is extending the Prescription Drug Fee User Act (PDUFA) goal date for the Company's supplemental biologics license application (sBLA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease (PD) from September 6, 2013 to December 6, 2013. Commenting on the extension, Adrian Adams, CEO and President of Auxilium Pharmaceuticals, said, "While we are disappointed in any delay of approval, we remain confident in the XIAFLEX Peyronie's program and are committed to working with the FDA while they complete their review. We are continuing to prepare for commercialization in Peyronie's disease, assuming FDA approval by the revised PDUFA date." According to the Company, the FDA has not requested for additional clinical studies to be performed prior to the revised PDUFA action date. The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/AUXL]
Accuray Incorporated Research Report
On August 27, 2013, Accuray Incorporated (Accuray) reported its financial results for Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). The Company's net revenue declined 15.6% YoY to $84.9 million during the quarter and dropped 22.8% YoY to $316 million for full-year FY 2013. Net loss attributable to stockholders was $18.7 million, or $0.25 per diluted share, in Q4 FY 2013, compared to net loss of $20.3 million, or $0.28 per diluted share, in Q4 FY 2012. For full-year FY 2013, net loss attributable to stockholders was $103.2 million, or $1.41 per diluted share, compared to net loss of $72.0 million, or $1.02 per diluted share, in full-year FY 2012. Commenting on the results, Joshua H. Levine, President and Chief Executive Officer of Accuray, said, "This was the second quarter in which we have shown growth and improvement in new order volume, driven by the actions we have taken to improve the commercial focus and execution of our business. I am encouraged that while we have seen improved commercial momentum, at the same time we have also reduced operating expenses, resulting in significantly lower operating losses and cash usage." The Full Research Report on Accuray Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/ARAY]
BioScrip Inc. Research Report
On August 26, 2013, BioScrip Inc. (BioScrip) announced that it has completed the previously announced acquisition of the business of CarePoint Partners Holdings LLC and its subsidiaries (collectively, CarePoint Partners). According to the Company, the acquisition of CarePoint Partners will enable BioScrip to provide home infusion services to over 100,000 patients annually. Rick Smith, President and CEO of BioScrip said, "This transaction marks another step in our strategy to build national scale in our core infusion business. We continue to see significant acquisition opportunities for additional growth, market expansion and consolidation in this highly-fragmented industry." The Full Research Report on BioScrip Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/BIOS]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
|SOURCE Investors' Reports|
Copyright©2012 PR Newswire.
All rights reserved